MedTrace Logo

Electrophysiologic Mechanisms of Ketamine Antidepressant Response

NCT07768618 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-08-17

No results posted yet for this study

Summary

This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms.

Participants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg/kg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.

Conditions

Interventions

DRUG

Ketamine

Participants will receive one subanesthetic intravenous ketamine infusion administered at a dose of 0.5 mg/kg over 40 minutes during admission to the Epilepsy Monitoring Unit. The infusion will be supervised by a psychiatrist experienced in ketamine administration and conducted under continuous clinical monitoring. Intracranial sEEG recordings, behavioral assessments, and symptom measures collected before and approximately 24 hours after infusion will be used to evaluate electrophysiologic biomarkers associated with antidepressant response

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Carl Hacker, MD, PhD · Emory University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2031-12-31
Completion
2031-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07768618 on ClinicalTrials.gov